Network News 9 – April 2003

In this issue: Report Card on HIV/AIDS in Prisons 2002 AGM Highlights Awards for Action on HIV/AIDS and Human Rights CIDA Funds Network Project in Kenya, Zambia New Project to Address Disability, Income Security Comments and Feedback Other Network News 2002/2003 Board Network Staff, Interns, and Summer Students Important Dates New Resources

HIV/AIDS Policy and Law Review 8(1) April 2003

FEATURES The UNGASS Declaration of Commitment on HIV/AIDS: One Year Later The UNGASS Declaration of Commitment on HIV/AIDS: A Review of Legislation in Six Southern African Countries CANADIAN NEWS Mandatory HIV Testing Used to Bar Potential Immigrants Troubled Times for Canada’s Medical Marijuana Program House of Commons Committee Holds Hearings on AIDS Survey Reveals Human … Read more

The UNGASS Declaration of Commitment on HIV/AIDS: One Year Later – HIV/AIDS Policy & Law Review 8(1)

The article reviews the process leading up to the Declaration and describes the limitations of the Declaration’s explicit and implicit recognition of human rights. It summarizes information provided by countries one year later to the Secretary-General and to UNAIDS on their progress in meeting the goals and targets of the Declaration, particularly with regard to … Read more

The UNGASS Declaration of Commitment on HIV/AIDS: A Review of Legislation in Six Southern African Countries – HIV/AIDS Policy & Law Review 8(1)

This article reviews legislation of six Southern African countries to determine what progress has been made after the UNGASS Declaration of Commitment on HIV/AIDS, particularly with regard to paragraph 58 on human rights and paragraph 69 on rights in the workplace. Related Publications HIV/AIDS Policy and Law Review 8(1) April 2003

Patents, International Trade Law, and Access to Essential Medicines

This Q&A answers some common questions about patents and international trade agreements. The rules on drug patents in international trade agreements and domestic laws affect the availability and affordability of medicines. This document explains the connection between patent issues and access to affordable drugs, to help inform advocates for the health of people in developing … Read more

HIV Vaccines for Developing Countries: Advancing Research and Access – Summary Report

This report is intended to complement and build on prior documents produced by the Canadian HIV/AIDS Legal Network related to human rights and HIV vaccine development. The report is part of a larger project led by the Canadian HIV/AIDS Legal Network to facilitate dialogue among researchers, funders, affected communities, national governments and the international community … Read more

Letter to Prime Minister Jean Chrétien re: Access to Affordable Medicines and the WTO of 17 December 2002

“Thank you for your acknowledgement on 9 January 2003 of the joint and detailed letter on Access to Affordable Medicines and the WTO of 17 December 2002, sent by ICAD and twenty-six nongovernmental and civil society organizations, along with six individuals. “We appreciate your acknowledgement of our letter, but regret that you have not provided … Read more

Hazel Tau and Others v. GlaxoSmithKline SA (Pty) Ltd. and Others – Submission of the Canadian HIV/AIDS Legal Network to the Competition Commission of South Africa

“The purpose of this submission is three-fold. First, the Network would like to express its support for the complaint lodged on 19 September 2002 by Hazel Tau and ten others… “Second, the Network would like to place before the Commission the recent judgment of the Supreme Court of Canada in Apotex Inc. v. Wellcome Foundation … Read more

Letter to Prime Minister Jean Chrétien and International Trade Minister Pierre Pettigrew re: Access to Affordable Medicines for Developing Countries and Canada at the World Trade Organization

“As Canadian members of civil society, the undersigned join in expressing to you our very deep concern about the Canadian government’s position at the World Trade Organization in current negotiations on the issue of access to affordable medicines in developing countries. We have a number of specific concerns outlined below…”